Hirokuni Mizoguchi
Overview
Explore the profile of Hirokuni Mizoguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
3
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karasawa H, Mizoguchi H, Choi B, Hsieh C, Miyano M, Moriya Y, et al.
Regen Ther
. 2024 Nov;
26:967-980.
PMID: 39524180
The 6th Asia Partnership Conference of Regenerative Medicine (APACRM) was held in person with online on April 20, 2023, to promote the regulatory harmonization of regenerative medicine products throughout Asia....
2.
Mizoguchi H, Zhang A, Gupta P, Komuro M, Cheun W, Chiu C, et al.
Regen Ther
. 2024 Jul;
26:334-345.
PMID: 39036442
Gene therapies, which include viral-vector gene delivery, genome editing, and genetically modified cell therapy, are innovative treatments with the potential to address the underlying genetic causes of disorders and to...
3.
Mizoguchi H, Fleischmann T, Komuro M, Hirai T, Ikeda A, Saito K, et al.
Expert Opin Biol Ther
. 2024 Jun;
24(6):529-542.
PMID: 38919146
Introduction: Recombinant viral-based gene therapy products, such as those incorporating adeno-associated viruses (AAVs), fall under the category of genetically modified organisms (GMOs). The European Union (EU) countries and Japan must...
4.
Mizoguchi H, Yamanaka T, Kano S
Drug Discov Today
. 2016 Jul;
21(10):1681-1689.
PMID: 27371505
Orphan drug legislation has contributed enormously to promote drug development for rare diseases but further effective and sustainable approaches are required. This study focused on the difference of rare disease...